HSBC share price set for Monday test after Singapore insurance review
18 January 2026
1 min read

HSBC share price set for Monday test after Singapore insurance review

London, Jan 18, 2026, 08:00 GMT — The market has closed.

HSBC shares dipped 0.4% in London Friday following the launch of a strategic review into its Singapore insurance arm. With markets closed Sunday, investors will revisit the news when trading restarts Monday. 1

This review is crucial as it touches on HSBC’s strategy for selling wealth products in Asia and how much control it plans to keep over that process. It also comes after a solid rally in big bank stocks, a time when investors usually tighten their grip on “nice-to-have” units and zero in on returns.

HSBC confirmed it’s reviewing its insurance unit in Singapore, HSBC Life Singapore, which it formed after buying AXA’s local insurance business. The bank is exploring all possibilities for this “insurance manufacturing” division but hasn’t reached a decision yet, CEO Georges Elhedery said amid a wider corporate shake-up. Bloomberg Intelligence analysts Steven Lam and Grace Huang noted that a sale could draw solid interest from global insurers. Singapore regulators, however, turned down Allianz’s bid to acquire a majority stake in Income Insurance earlier this year following public opposition, according to 5 .

In London, the stock ended at 1,232 pence on Jan 16, slipping 0.39% from the previous close. It fluctuated between 1,226.6 and 1,240.0 pence, with roughly 28.8 million shares traded, per 6 .

In New York, the ADR closed at $82.53, slipping 31 cents after fluctuating between $82.31 and $83.18 during the session. Trading volume hit roughly 1.5 million shares, per market data.

A “strategic review” means a formal evaluation of options — whether to keep, partner, sell, or reshape an asset — though the final outcome usually isn’t clear from the outset. These reviews can stretch out over time, leaving the market to speculate in the meantime.

Kenny Tang Sing-hing, chairman of the Hong Kong Institute of Financial Analysts and Professional Commentators, said it “makes sense” for HSBC to consider exiting Singapore’s insurance market to focus on demand in Hong Kong and mainland China. HSBC confirmed the review pertains solely to its Singapore insurance unit and is exploring “all options,” with no final decision reached yet. 2

The downside is clear: no deal, no clear message, and months of uncertainty ahead. Even if HSBC lands a buyer, the terms—and how the bank continues to provide insurance to clients—will influence investor sentiment on the deal.

Hong Kong’s High Court is set to hold a hearing on Jan 23 to review HSBC’s plan to take Hang Seng Bank private, Reuters reported. This comes after shareholders gave the green light to the proposal. 3

HSBC is set to release its full-year 2025 results on Feb 25. Investors want to see how the Singapore review will impact capital, costs, and the bank’s wealth strategy across Asia. 4

Stock Market Today

LSEG share price heads into Monday after AI jitters hit London Stock Exchange Group stock

LSEG share price heads into Monday after AI jitters hit London Stock Exchange Group stock

8 February 2026
London Stock Exchange Group shares fell 1.1% to 7,502p Friday, closing out a third straight weekly decline and an 8% drop for the week. The selloff followed renewed concerns over AI disruption after a new Claude plug-in from Anthropic and caution over Big Tech’s AI spending. LSEG bought back 256,419 shares on Feb. 5. Investors await Monday’s open and LSEG’s FY25 results webcast on Feb. 26.
Anglo American share price slips after BofA downgrade as De Beers review looms

Anglo American share price slips after BofA downgrade as De Beers review looms

8 February 2026
Anglo American shares closed at 3,435 pence on Friday, down 0.75%, after BofA Global Research downgraded the miner to “neutral” over valuation and execution risks. The bank raised its price target to 3,600 pence but flagged a long wait for Teck synergies and uncertainty around De Beers. Investors await full-year results and updates on deals and disposals on Feb. 20.
GSK stock price: EU nod for Nucala in COPD puts the focus on Monday trade

GSK stock price: EU nod for Nucala in COPD puts the focus on Monday trade

8 February 2026
GSK shares closed Friday up 0.8% at 2,198 pence after the EU approved expanded use of Nucala for adults with uncontrolled COPD. Chairman Jonathan Symonds bought 2,500 shares earlier in the week. The stock is up 17% over the past week and nearly 49% in 12 months. GSK trades ex-dividend on Feb. 19.
Glencore share price drops 2.5% as copper cools and takeover filings stack up ahead of Monday
Previous Story

Glencore share price drops 2.5% as copper cools and takeover filings stack up ahead of Monday

RELX share price slips despite buyback notice as February results loom
Next Story

RELX share price slips despite buyback notice as February results loom

Go toTop